P

Pierrel SpA
MIL:PRL

Watchlist Manager
Pierrel SpA
MIL:PRL
Watchlist
Price: 1.745 EUR Market Closed
Market Cap: 95.9m EUR
Have any thoughts about
Pierrel SpA?
Write Note

Relative Value

The Relative Value of one PRL stock under the Base Case scenario is 2.969 EUR. Compared to the current market price of 1.745 EUR, Pierrel SpA is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PRL Relative Value
Base Case
2.969 EUR
Undervaluation 41%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
73
vs Industry
39
Median 3Y
8.4
Median 5Y
10.1
Industry
2.6
Forward
3.1
vs History
73
vs Industry
15
Median 3Y
95.3
Median 5Y
103.2
Industry
23
Forward
144
vs History
73
vs Industry
32
Median 3Y
30.6
Median 5Y
43.1
Industry
17.8
vs History
30
vs Industry
16
Median 3Y
30.1
Median 5Y
30
Industry
25.4
vs History
58
vs Industry
21
Median 3Y
9.6
Median 5Y
10.1
Industry
2.2
vs History
73
vs Industry
33
Median 3Y
9
Median 5Y
10.5
Industry
2.8
Forward
3.7
vs History
73
vs Industry
42
Median 3Y
13.1
Median 5Y
15.7
Industry
5.4
vs History
73
vs Industry
21
Median 3Y
53.6
Median 5Y
58.5
Industry
13.7
Forward
16.3
vs History
73
vs Industry
13
Median 3Y
77.8
Median 5Y
83.6
Industry
17.2
Forward
30.9
vs History
73
vs Industry
28
Median 3Y
33.2
Median 5Y
45.5
Industry
16.5
vs History
vs Industry
Median 3Y
-34
Median 5Y
-71.5
Industry
19.3
vs History
58
vs Industry
38
Median 3Y
4.7
Median 5Y
4.9
Industry
2

Multiples Across Competitors

PRL Competitors Multiples
Pierrel SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Pierrel SpA
MIL:PRL
95.9m EUR 2.9 30.6 17.6 31.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.4B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 169.3 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
IT
P
Pierrel SpA
MIL:PRL
Average P/E: 32.8
30.6
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top